NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM

IONA-MM

NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months

Sponsor

Sanofi

---

ClinicalTrials.gov Identifier: NCT04458831

Official Title: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

First Posted : July 7, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: isatuximab SAR650984

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Carfilzomib

---

Isatuximab : National Cancer Institute

Isatuximab : MedlinePlus Drug Information

---

Locations

United States, Arkansas

United States, California

United States, Florida

United States, Kansas

United States, Maine

United States, Michigan

United States, Missouri

United States, New Jersey

United States, North Carolina

United States, Ohio

United States, South Carolina

United States, South Dakota

United States, Texas

Puerto Rico

Europe

Austria

Belgium

Netherlands

France

Germany

Italy

Switzerland

Asia

Japan